09.04.24
Magtein, a patented magnesium L-threonate ingredient marketed by ThreoTech, was associated with improved sleep quality, especially during deep and REM sleep stages, as well as subjective improvements to mood, energy, alertness, and daily activity and productivity. The findings of this clinical study were recently published in Sleep Medicine: X.
In the randomized, double-blind, placebo-controlled, parallel-arm trial, 80 people between the ages of 35 and 55 who self-reported poor sleep quality at baseline were given either a gram of magnesium L-threonate or a placebo for three weeks.
Nightly sleep parameters were assessed through Oura Ring trackers, while the group was also assessed for subjective measures of sleep quality through the Insomnia Severity Index, Leeds Sleep Evaluation Questionnaire, and Restorative Sleep Questionnaire.
The magnesium L-threonate group maintained good sleep quality and daily functioning throughout the treatment, while, overall, the placebo group saw declines in both measures.
Oura ring results showed that supplementation was associated with better deep sleep and REM sleep scores, light sleep time, and activity and readiness parameters of activity score, activity daily movement scores, readiness scores, readiness activity balance, and readiness sleep balance.
Significant improvements were found over placebo in questionnaires which covered behavior upon awakening, energy and daytime productivity, grouchiness, mood, and mental alertness. Magnesium L-threonate was safe and well tolerated.
“This study confirms numerous consumers’ reviews indicating restorative sleep when taking Magtein,” said Jennifer Gu, PhD, vice president of research and development at ThreoTech and one of the study’s principal investigators. “Given our growing understanding of brain bioavailable magnesium, we hypothesized that Magtein would also have benefits for sleep. Our objectives were to investigate the impact of Magtein supplementation on sleep parameters, as well as on mood, daytime energy, and other related measurements.”
In the randomized, double-blind, placebo-controlled, parallel-arm trial, 80 people between the ages of 35 and 55 who self-reported poor sleep quality at baseline were given either a gram of magnesium L-threonate or a placebo for three weeks.
Nightly sleep parameters were assessed through Oura Ring trackers, while the group was also assessed for subjective measures of sleep quality through the Insomnia Severity Index, Leeds Sleep Evaluation Questionnaire, and Restorative Sleep Questionnaire.
The magnesium L-threonate group maintained good sleep quality and daily functioning throughout the treatment, while, overall, the placebo group saw declines in both measures.
Oura ring results showed that supplementation was associated with better deep sleep and REM sleep scores, light sleep time, and activity and readiness parameters of activity score, activity daily movement scores, readiness scores, readiness activity balance, and readiness sleep balance.
Significant improvements were found over placebo in questionnaires which covered behavior upon awakening, energy and daytime productivity, grouchiness, mood, and mental alertness. Magnesium L-threonate was safe and well tolerated.
“This study confirms numerous consumers’ reviews indicating restorative sleep when taking Magtein,” said Jennifer Gu, PhD, vice president of research and development at ThreoTech and one of the study’s principal investigators. “Given our growing understanding of brain bioavailable magnesium, we hypothesized that Magtein would also have benefits for sleep. Our objectives were to investigate the impact of Magtein supplementation on sleep parameters, as well as on mood, daytime energy, and other related measurements.”
